NXL

Nexalin is a pre-commercial neurostimulation shell trading like a lottery ticket. FY2025 revenue was just $302K — up 79% but off a trivial base, and the five-year history ($144K→$1.32M→$111K→$169K→$302K) shows no durable ramp, only noise. That revenue is legacy Gen-1 device licensing and electrode sales; U.S. marketing of new Gen-1 units has been paused since the FDA's December 2019 CES reclassification, so the real business — Gen-2 SYNC (Alzheimer's/dementia) and Gen-3 HALO (insomnia) — is still in Q-Submission and clinical-trial stage with no clearance and no product revenue. Against that $302K top line the company burned an $8.22M net loss (-2,726% net margin) and -$4.96M of operating cash. The 80% gross margin is meaningless at this scale.

The filing itself removes any ambiguity: management discloses 'substantial doubt about its ability to continue as a going concern,' a failure to meet Nasdaq's minimum bid price (the stock is $0.36), and material weaknesses in internal control over financial reporting (segregation of duties and IT access). The stated plan is to fund operations through an at-the-market (ATM) offering 'though there can be no assurance that sufficient capital will be available on acceptable terms, or at all.' That is the whole story: survival depends on selling stock into a $0.36 tape. Share count already rose 54.7% in one year (13.3M→20.6M) on top of the September 2022 IPO and July 2024 / May 2025 follow-ons — existing holders are being diluted continuously just to keep the lights on.